**2004**

**Cell Genesys Launches Phase 3 Clinical Trial of GVAX® Prostate Cancer Vaccine**

The company's lead oncology product platform, GVAX® prostate cancer vaccine, enters Phase 3 clinical trials. The trials are designed to compare our vaccine therapy to standard chemotherapy in patients with advanced prostate cancer.

![Cancer Cell](image1)

**2001**

**Cell Genesys Launches Ceregene**

Ceregene, Inc. was launched by Cell Genesys as a majority-owned subsidiary focused on gene therapies for neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. Cell Genesys believes that leveraging its neurodegenerative gene therapy technologies and patents would maximize the potential of these assets thereby creating further shareholder value. Ceregene is based in San Diego, CA.

![Ceregene Logo](image2)

**2000**

**Cell Genesys Raises $250 Million**

Cell Genesys sold a portion of its holdings in Abgenix, raising more than $250 million. These resources enabled Cell Genesys to expand its product development activities with an increased emphasis on clinical stage programs in the cancer area.

![Cell Genesys Logo](image3)

**2003**

**Cell Genesys Signs Global Alliance with Novartis AG: Oncolytic Virus Therapies**

Under the agreement, Cell Genesys acquired exclusive worldwide rights to the oncolytic virus therapy products and certain related intellectual property of Genetic Therapy, Inc. (GTI), an affiliate of Novartis.

![Cell Genesys Logo](image4)

**2002**

**Cell Genesys Establishes Manufacturing Capabilities for Phase 3 Trials**

Cell Genesys completed construction of three state-of-the-art specialized facilities for producing non patient-specific cancer vaccines, patient-specific cancer vaccines, and oncolytic virus therapies. With approximately 135,000 square feet of GMP manufacturing space, Cell Genesys is now well positioned to manufacture products for multiple Phase 3 clinical trials and potential commercial launch.

![Cell Genesys Logo](image5)
1997
Cell Genesys Acquires Somatix Therapy Corporation
Cell Genesys acquired Somatix, providing Cell Genesys with
a promising clinical stage product platform—GVAX® cancer
vaccines—as well as an extensive technology and patent estate.

1996
Cell Genesys Launches Abgenix
Cell Genesys spun out its antibody therapy business into a
wholly-owned subsidiary, Abgenix, Inc. Abgenix went public in
1998 and became a Nasdaq-100® company in 2000. Cell Genesys
continues to retain an equity interest in Abgenix.

1993
Cell Genesys—A Public Company
Cell Genesys completed an initial public offering in January
1993 securing $44 million in funding. A secondary offering in
November 1993 raised another $38 million. (Nasdaq: CEGE)

1988
Cell Genesys Begins
Cell Genesys was incorporated in 1988 and received its first
financing in 1989 from the Mayfield Fund. The company initially
had three areas of technology and product development—
gene and cell therapy, human monoclonal antibodies and
gene-activated therapeutic proteins.